Financial Performance - The company incurred net losses of $106.2 million and $86.9 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $480.4 million as of December 31, 2025[216]. - The company has not generated any revenue from product sales to date and does not expect to do so in the foreseeable future[216]. - The company will require substantial additional capital to finance its operations and may need to pursue equity or debt financings, which could dilute existing stockholders[222]. - The company does not anticipate paying any cash dividends on its capital stock in the foreseeable future, with capital appreciation being the sole source of gain for stockholders[404]. - Future sales of common stock could result in substantial dilution for existing stockholders, with a registration statement filed for the offering of up to $75 million in common stock[414]. - Quarterly operating results may fluctuate significantly, influenced by various factors including clinical trial results and collaboration arrangements[406]. Going Concern and Capital Requirements - As of December 31, 2025, the company had cash and cash equivalents and marketable securities of $144.2 million, which are insufficient to fund bel-sar through regulatory approval[221]. - The company faces substantial doubt about its ability to continue as a going concern for at least twelve months following the filing of the Annual Report[221]. - The company has no committed external source of funds and may face challenges in obtaining additional financing on acceptable terms[222]. - The company’s auditors have issued a "going concern" audit opinion, indicating substantial doubt about its ability to continue as an ongoing business[224]. - If the company fails to raise capital as needed, it may have to delay or eliminate clinical trials and research and development programs[223]. Research and Development - The company anticipates significant increases in research and development expenses as it continues clinical development for bel-sar and other product candidates[216]. - The success of the company heavily relies on the development and commercialization of its only product candidate, bel-sar, which is focused on multiple oncology indications[232]. - The company has initiated a global Phase 3 trial for bel-sar but has not yet completed pivotal clinical trials necessary for regulatory approval[244]. - The company expects to focus its resources on the development of bel-sar in the near term, which may limit its commercial opportunities if additional product candidates are not developed[245]. - The lengthy and unpredictable regulatory approval process may result in delays or failure to market product candidates, significantly harming the company's business prospects[238]. Regulatory Risks - Regulatory approval for bel-sar is subject to comprehensive regulation by the FDA and foreign authorities, and failure to obtain such approval would materially impair revenue generation[236]. - The approval process for bel-sar may be complicated due to its requirement for a drug delivery device and activation by a laser, increasing regulatory risks[247]. - The company must establish commercially viable supply and manufacturing relationships to support clinical development and market demand for bel-sar if approved[230]. - Regulatory authorities may require additional warnings or limitations on product labeling if undesirable side effects are identified post-approval[264]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) for approved product candidates, which could include distribution restrictions[273]. Clinical Trials and Market Acceptance - The company faces risks related to the commercial acceptance of bel-sar by patients, the medical community, and third-party payors, which are critical for revenue generation[235]. - Delays in patient enrollment for clinical trials could hinder the receipt of necessary regulatory approvals[249]. - The company may face challenges in recruiting sufficient eligible patients due to competition and perceived risks associated with product candidates[250]. - Conducting clinical trials outside the United States may not guarantee acceptance of data by the FDA or foreign regulatory authorities, potentially requiring additional trials[252]. - Adverse events or side effects identified during clinical trials could delay or prevent marketing approval and affect the product's market acceptance[262]. Intellectual Property and Legal Risks - The ability to protect proprietary rights is crucial for commercial success, with potential challenges from third-party patent claims[324]. - Legal disputes over intellectual property rights can be costly and may divert management resources, impacting business operations[329]. - The company may face potential patent infringement claims that could result in substantial costs and delays in product development and commercialization[342]. - Litigation related to patent rights is common in the biotechnology industry, which may hinder the company's ability to operate effectively[343]. - The complexity of patent laws and potential changes could affect the ability to protect intellectual property effectively[341]. Market and Competitive Landscape - The company faces intense competition from established pharmaceutical and biotechnology companies, which may have greater resources and capabilities[312]. - The market opportunity for bel-sar may be smaller than estimated, adversely affecting revenue and profitability[315]. - Regulatory approval of product candidates may be limited by the availability and pricing of competitors' products, affecting demand[313]. - The company may encounter challenges in obtaining adequate coverage and reimbursement from third-party payors, impacting product acceptance[314]. Compliance and Regulatory Environment - Compliance with healthcare regulatory laws is critical, as violations could lead to significant penalties and operational disruptions[319]. - Legislative and regulatory changes in the healthcare system may adversely affect the approval and profitability of current and future product candidates[320]. - Increased state-level initiatives in the U.S. are aimed at controlling pharmaceutical pricing, which could pressure product demand and pricing[321]. - Future healthcare reforms may limit government payments for healthcare products, potentially reducing demand for product candidates[322]. Data Privacy and Cybersecurity - Cybersecurity incidents could disrupt product development programs and lead to unauthorized access to sensitive information, resulting in financial and reputational harm[364]. - The company may face significant costs related to compliance with evolving data privacy laws, including the California Consumer Privacy Act (CCPA) and other state regulations[373]. - Non-compliance with data protection laws could lead to government enforcement actions, private litigation, and increased operational costs[370]. - The GDPR imposes fines of up to €20 million or 4% of worldwide annual turnover for violations, which increases compliance burdens for the company[379]. Management and Operational Challenges - The potential loss of key management personnel could impair the company's business strategy and competitiveness[355]. - The company anticipates significant growth in operations, particularly in sales and marketing, which may strain management resources and disrupt operations[394]. - The company currently lacks marketing and sales organization and experience, which may hinder its ability to generate product revenue[308]. - Establishing an in-house marketing organization will require significant capital expenditures and management resources[308].

Financial Performance - The company reported a net loss of $324.2 million for the year ended December 31, 2025, compared to a net loss of $243.8 million for 2024, with an accumulated deficit of $920.5 million as of December 31, 2025[442]. - The company expects to continue incurring substantial losses as it advances its research and development efforts, with no immediate expectation of profitability[442]. - The company will require substantial additional capital to finance operations and achieve business objectives, with potential delays or reductions in research programs if capital is not raised[446]. - Adverse global economic conditions, including inflation and geopolitical events, could negatively impact the company's operations and financial performance[486]. - Changes in U.S. government policies, including tariffs and reductions in federal research funding, could adversely affect the company's business[487]. Product Development and Clinical Trials - The company is conducting a Phase 2/3 registrational trial for EIK1001 in combination with pembrolizumab for advanced melanoma and a Phase 2 trial for non-small cell lung cancer[439]. - EIK1001 is the most advanced product candidate, currently in a Phase 2/3 registrational trial for advanced melanoma and a Phase 2/3 trial for NSCLC[491]. - The company has not completed any pivotal clinical trials for its product candidates, which are primarily in preclinical or early-stage clinical development[491]. - The company faces high risks of failure in clinical development, with potential delays in obtaining regulatory approvals that could extend commercialization timelines by many years[492]. - The regulatory approval process is lengthy and unpredictable, with no product candidates having received approval to date, which could significantly harm the business[503]. Research and Development - The company has invested heavily in the development of its product candidates, which are still in preclinical or clinical development, and expects to continue this trend[454]. - The company has invested significantly in research and development to enhance its technology platform, which includes proprietary software, hardware, and datasets, but faces risks related to timely and cost-effective implementation of enhancements[462]. - The company relies on its technology platform to improve drug development speed and success probability, but there is uncertainty regarding its ability to identify clinically relevant biomarkers or additional product candidates[459]. Regulatory and Compliance Risks - The company must maintain compliance with various regulatory standards and may face significant penalties for noncompliance, which could impact its operations and reputation[471]. - The company is subject to numerous foreign regulatory requirements, which may differ significantly from U.S. regulations, adding complexity to the approval process[508]. - The company may face significant financial penalties if it or any future partner fails to comply with regulatory requirements related to product development and safety monitoring[534]. Intellectual Property Risks - The company faces risks related to intellectual property, including the potential inability to obtain sufficient patent protection for product candidates, which could allow competitors to develop similar products[573]. - The company has in-licensed certain patents related to EIK1001 but lacks composition of matter patents for EIK1001 as a sole active ingredient, limiting competitive protection[575]. - The company may face challenges in enforcing patent rights, which could result in loss of exclusivity or narrowed patent claims, adversely affecting its business prospects[581]. - The company may face various patent disputes that could adversely affect its exclusivity and patent claims, potentially leading to significant costs and operational impacts[587]. Collaboration and Partnerships - The company has entered into collaborations with several entities, including Seven and Eight Biotherapeutics and MSD International Business GmbH, to advance research and development activities[472]. - Collaborations are complex and may not lead to efficient development or commercialization, potentially requiring the company to raise additional capital[475]. - The company may need to enter collaborations or licensing arrangements, which could result in relinquishing valuable rights to its technologies or future revenue streams[453]. Market and Competitive Landscape - The company faces substantial competition from larger pharmaceutical and biopharmaceutical companies, which may hinder its ability to successfully develop and commercialize its products[542]. - Market acceptance of product candidates is uncertain and depends on factors such as safety, efficacy, cost, and competition, which could affect revenue generation[536]. - The company estimates that the market opportunities for its product candidates may be smaller than anticipated, with actual market growth subject to numerous uncertainties[539]. Operational Challenges - The company may encounter challenges in attracting and retaining qualified personnel due to intense competition in the biopharmaceutical sector, which could impede its business objectives[466]. - The company faces significant product liability risks during clinical trials, which could adversely affect its financial condition and operational results[470]. - Delays in participant enrollment or withdrawals from trials could compromise data quality and increase costs[497].

Financial Performance and Projections - The company has incurred significant losses since its inception in November 2019, with an accumulated deficit of $1,184.1 million as of December 31, 2025, and expects to continue incurring losses for the foreseeable future [138]. - The company has no products approved for commercial sale and has not generated any revenue from product sales, relying primarily on financing through common stock and convertible securities [138]. - The company anticipates substantial increases in expenses and operating losses as it expands research and development efforts, advances clinical candidates, and seeks regulatory approvals [139]. - The company must successfully identify, develop, and commercialize products to achieve profitability, which involves completing clinical trials and obtaining regulatory approvals [141]. - The company has not yet demonstrated the ability to complete late-stage clinical trials or commercialize products, which may impact its future success [149]. - The company expects to continue to expend significant resources for product development and may seek additional capital due to favorable market conditions, which could divert management from day-to-day activities [153]. Funding and Financial Obligations - The company has contingent obligations from acquisitions, including up to $365.0 million in milestone payments related to navacaprant and up to $450.0 million in sales-based milestones [144]. - Under its license agreements, the company is obligated to pay up to $720.0 million in commercial milestone payments to Amgen and $422.4 million to Vanderbilt University upon achieving certain milestones [145][146]. - The company may need to issue equity or incur debt to satisfy its payment obligations, which could dilute stockholder value and affect its financial position [147]. - The company raised aggregate net proceeds of $19.7 million and $13.7 million in 2025 and 2024, respectively, through sales of common stock under an ATM agreement [156]. - The company entered into a loan agreement with K2 HealthVentures LLC, which includes covenants that may limit its ability to incur additional debt [156]. Competition and Market Environment - The company operates in a highly competitive environment, facing risks related to drug development timelines and regulatory approvals that could adversely affect its business [142]. - The biotechnology industry is highly competitive, with significant risks from larger companies and rapid technological changes [180]. - The company faces intense competition for skilled personnel, particularly in Massachusetts and California, which may impact its ability to attract and retain key employees [173]. - The company is focused on acquiring and in-licensing assets and technologies to enhance its product pipeline and precision neuroscience tools [174]. Clinical Development and Regulatory Challenges - Clinical and preclinical drug development processes are lengthy and expensive, with uncertain outcomes that could delay regulatory approvals [194]. - The company must conduct extensive preclinical and clinical trials to demonstrate the safety and efficacy of its product candidates, which is a lengthy and costly process [195]. - Delays in clinical trials can arise from various factors, including difficulties in patient recruitment, regulatory approvals, and adherence to clinical protocols [198]. - The transition to the EU Clinical Trials Regulation (CTR) may impact the company's development plans, as it introduces a centralized application process for multi-center trials [201]. - The company faces risks associated with conducting clinical trials in foreign countries, including cultural differences and regulatory challenges [197]. - Adverse side effects identified during clinical trials could lead to delays in marketing approval or limit the commercial profile of approved products [208]. Regulatory Compliance and Risks - Regulatory approval processes are lengthy and unpredictable, and failure to obtain timely approval could significantly harm the business [232]. - The company has not previously submitted a New Drug Application (NDA) and lacks experience in this area, which could complicate the approval process [233]. - Non-compliance with regulatory requirements may lead to significant penalties, including civil or criminal penalties, and could adversely affect the company's value and operating results [241]. - Changes in FDA policies or additional government regulations may delay or prevent regulatory approval of product candidates, impacting profitability [242]. - The FDA actively enforces laws prohibiting off-label promotion, and violations could result in significant liability for the company [243]. Intellectual Property and Legal Risks - The company is party to various intellectual property license agreements, and any breach or termination could harm its ability to develop and commercialize product candidates [297]. - Future royalty obligations from licensed technologies may be significant, impacting profitability even if products are successfully developed [301]. - The ability to enforce patent rights depends on licensors, and failure to conduct necessary legal actions could adversely affect product development [304]. - The company may face challenges in maintaining existing intellectual property rights, which could lead to abandoning research programs or product candidates [302]. - The company may need to initiate costly litigation to defend its patent rights, which could divert resources from core business activities [333]. Operational and Supply Chain Risks - The company relies on third-party manufacturers for the production of product candidates, which increases the risk of supply disruptions and delays in clinical trials [285]. - The company does not have long-term supply agreements with manufacturers, making it vulnerable to unexpected supply losses [285]. - The company expects to continue relying on third-party manufacturers for commercial supply, which entails risks related to compliance with Good Manufacturing Practices (cGMP) and quality control [286]. - The company depends on third-party clinical research organizations (CROs) for conducting preclinical studies and clinical trials, which poses risks if these parties fail to meet obligations [292]. Data Privacy and Compliance Costs - The company faces potential liability related to the privacy of health information utilized in product development and clinical trials, with compliance costs expected to increase in the future [271]. - The company may incur substantial operational costs to comply with U.S. federal and state data privacy and security laws, which could lead to significant fines and penalties if compliance is not met [277]. - The General Data Protection Regulation (GDPR) imposes stringent operational requirements for processing personal data in the European Economic Area, with potential fines up to €20 million or 4% of global turnover for non-compliance [278]. - The California Consumer Privacy Act (CCPA) requires businesses to provide disclosures regarding personal information collection and may increase compliance costs and potential liability for the company [276].

Financial Performance - For the year ended December 31, 2025, the net loss was approximately $34.5 million, or $0.74 per share, compared to a net loss of $37.6 million, or $1.03 per share for 2024, representing a 8.5% improvement in loss per share [6]. - Long-term debt increased to $11.7 million in 2025 from $9.2 million in 2024, reflecting a rise of 27.4% [17]. - The accumulated deficit as of December 31, 2025, was $(216.6) million, compared to $(182.1) million in 2024, indicating an increase in the deficit of 18.9% [17]. Expenses - Research and development expenses decreased to $19.0 million in 2025 from $22.6 million in 2024, a reduction of $3.6 million, primarily due to lower manufacturing and personnel costs [7]. - General and administrative expenses for 2025 were $12.5 million, down from $13.8 million in 2024, reflecting a decrease of $1.3 million primarily due to reduced personnel costs [8]. - Total operating expenses for 2025 were $31.5 million, compared to $36.3 million in 2024, indicating a decrease of 13.5% [8]. Cash Position - The cash balance as of December 31, 2025, was $26.7 million, down from $41.7 million at the end of 2024 [10]. Clinical Trials and Research - The company amended the VERSATILE-003 Phase 3 clinical trial protocol to include progression-free survival (PFS) as an interim primary endpoint, potentially shortening trial duration and reducing costs [4]. - Early results from the NCI-led trial of PDS01ADC showed a median PFS of 9.6 months and a median PSA decline of 40% in patients with metastatic castration-resistant prostate cancer [4]. Intellectual Property - The company strengthened its intellectual property estate for PDS0101 with new patents granted in the U.S. and Japan, extending market protection into the 2040s [5].

Financial Performance - The net loss for the full year 2025 was $106.2 million, compared to a net loss of $86.9 million in 2024[17]. - The total operating loss for the full year 2025 was $112.8 million, compared to $96.1 million in 2024[20]. - General and administrative expenses decreased to $22.5 million for the full year 2025, down from $22.8 million in 2024, driven by reduced professional fees[17]. - Research and development expenses for the full year 2025 were $90.3 million, an increase from $73.3 million in 2024, primarily due to ongoing clinical trial costs[17]. - As of December 31, 2025, the company had cash and cash equivalents and marketable securities totaling $144.2 million, sufficient to fund operations into Q1 2027[17]. Clinical Trials and Developments - The ongoing Phase 3 CoMpass trial is expected to complete enrollment by mid-2026, with topline data anticipated in the second half of 2027[2]. - Initial three-month clinical data from the Phase 1b/2 NMIBC trial is expected in mid-2026[2]. - The ongoing Phase 2 trial for bel-sar in metastases to the choroid is on track to report early data in 2026, addressing a high unmet medical need[10]. - The company achieved 12-month stability for a new formulation designed for non-ocular solid tumors, starting with urologic oncology[8]. - The company has received FDA Fast Track designation for bel-sar in the treatment of early choroidal melanoma and metastases to the choroid[5].

Financial Performance - Total product revenue for the year ended December 31, 2025, was $37.1 million, an increase of 4.1% compared to $35.6 million in 2024[250]. - Gross profit for 2025 was approximately $26.5 million, representing a gross margin of 71.5%, up from 69.9% in 2024[256]. - Loss from operations improved by 10.4% to approximately $14.7 million in 2025, compared to $16.5 million in 2024, driven by revenue growth and gross margin improvement[260]. - Research and development expenses decreased by 33.2% to approximately $5.1 million in 2025, down from $7.6 million in 2024, due to the completion of the STAR-T clinical trial[257]. - Selling, general and administrative expenses increased by 5% to approximately $35.6 million in 2025, primarily due to higher legal and regulatory costs[258]. - Net interest expense for 2025 was approximately $2.6 million, an increase from $1.4 million in 2024, due to interest incurred on the credit facility[261]. - Benefit from income taxes was approximately $0.4 million for 2025, down from $1.7 million in 2024, due to the utilization of the New Jersey Technology Business Tax Certificate Transfer Program[265]. Strategic Initiatives - The company initiated a strategic workforce and cost reduction plan, resulting in a restructuring charge of approximately $0.5 million in 2025[259]. - The company expects to reach operating cash flow break-even in the second half of 2026 following the strategic workforce and cost reduction plan[252]. - The company plans to file a new De Novo application for DrugSorb-ATR with the FDA, following an appeal meeting that affirmed no safety-related issues with the device[250]. - The company initiated a Strategic Workforce and Cost Reduction Plan, reducing its workforce by approximately 10% and expects to reach operating cash flow break-even in the second half of 2026[275]. Financial Position - As of December 31, 2025, current assets were approximately $20.6 million and current liabilities were approximately $9.7 million[266]. - As of December 31, 2025, the company had approximately $7.8 million in cash, which may not be sufficient to fund operations beyond the next twelve months[276]. - An effective shelf registration statement allows the company to raise up to $150 million, with approximately $149.7 million available as of December 31, 2025[267]. - The company entered into a Loan and Security Agreement with Avenue Capital Group for up to $20 million, with the first tranche of $15 million disbursed under specific conditions[268]. - The Amended Loan and Security Agreement provides access to an additional $2.5 million, with an extension of the interest-only period to December 31, 2026, subject to FDA approval[281]. Capital Raising Activities - The company raised $6.25 million from a rights offering, with proceeds used to satisfy a debt covenant and release $5 million of restricted cash[273]. - The Company raised aggregate gross proceeds of $6.25 million from the Rights Offering, with $5.4 million net of fees[287]. - Participants received Units comprising one share of common stock and two Right Warrants, with the potential to issue an additional 6.25 million shares upon exercise[287]. - Approximately 1.4 million Series A Right Warrants were exercised at an exercise price of $1.13 per warrant, generating an additional $1.6 million in gross proceeds[287]. - The expiration date of the Series B Right Warrants was extended from April 10, 2025, to June 10, 2025[287]. - The Series B Right Warrants expired worthless due to the 5-day volume weighted average price of Common Stock being below the minimum required price of $2.00[287]. Tax and Valuation Considerations - The Company evaluates uncertain tax positions based on estimates and assumptions, which may differ from actual results[289]. - The fair value of warrants is estimated using the Black-Scholes or Monte Carlo pricing models, requiring significant estimates regarding inputs[295]. - Changes in assumptions used for estimating the fair value of warrants could materially affect the financial statements[298]. - The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense[291]. - Deferred tax assets are evaluated for valuation allowances based on expectations of future taxable income, which could impact financial statements[292]. Other Financial Metrics - The company reported a gain on foreign currency transactions of approximately $9.3 million in 2025, compared to a loss of $4.2 million in 2024, attributed to the increase in the Euro to U.S. dollar exchange rate[262]. - Loss on abandoned patents increased by approximately $0.2 million or 67.4%, totaling $0.6 million for the year ended December 31, 2025, compared to $0.3 million for 2024[264].

Biotechnology and Drug Development - As of December 31, 2025, the company manages a diverse portfolio of four wholly owned subsidiaries in the medical aesthetics and biopharmaceutical sectors[29]. - The divestiture of Elevai Skincare Inc. on January 16, 2025, allows the company to focus resources on biotechnology assets, enhancing growth opportunities[30]. - Northstrive Biosciences Inc. targets the obesity market, with over 40% of U.S. adults affected, projected to rise to 50% by 2030, creating a $100 billion market opportunity[32]. - The lead asset, EL-22, has completed a Phase 1 clinical trial in South Korea, showing safety and tolerability, with no dropouts due to adverse events[34]. - The company aims to submit an Investigational New Drug application for EL-22 in 2025, contingent on sufficient working capital[36]. - The second asset, EL-32, is in preclinical development, targeting muscle preservation in weight loss treatments, with promising results in mouse models[37]. - Northstrive Biosciences is developing EL-22, an engineered probiotic, with the potential to treat obesity while preserving muscle mass, targeting a market projected to reach $100 billion by 2030[62][78]. - EL-22 has shown a statistically significant increase in anti-myostatin IgG antibody concentration and a decrease in creatine kinase levels, indicating reduced muscle destruction[87]. - Northstrive Biosciences plans to complete an IND submission for EL-22 in 2025 and initiate clinical trials in the U.S. contingent upon FDA approval[86]. - Northstrive's EL-32 is positioned for muscle preservation in weight loss treatments, addressing an unmet need in the obesity treatment landscape[66]. - The weight-loss drug market, driven by GLP-1 receptor agonists, is experiencing significant growth, with existing drugs showing that up to 40% of weight loss may come from lean muscle mass loss[79]. - The biotechnology market is projected to grow significantly, with the anti-obesity drug market potentially reaching $100 billion by 2030[98]. - The product candidates EL-22 and EL-32 are believed to represent the only oral myostatin formulations currently in development, providing a potential competitive advantage over existing injectable approaches[98]. - The success of the Licensed Products depends on successful completion of preclinical studies and clinical trials, as well as obtaining regulatory approvals[200]. - The commercial success of the Licensed Products will be contingent upon establishing manufacturing relationships and maintaining patent protection[200]. - The biotechnology subsidiary, Northstrive Biosciences, has not yet commercialized any therapeutic products, with lead asset EL-22 having completed a Phase 1 clinical trial in South Korea but not yet tested in the U.S.[192]. Financial Performance and Capital Requirements - As of December 31, 2025, the company had net working capital of $2,928,959, down from $4,251,867 in 2024, and an accumulated deficit of $21,017,440, increasing from $13,269,627 in 2024[159]. - The company incurred net losses of $7,747,813 for the year ended December 31, 2025, compared to $6,245,737 for the year ended December 31, 2024[161]. - Operating cash consumption significantly exceeds revenue, indicating unsustainable operations without continued access to capital markets[162]. - The company requires significant additional capital to develop its products and businesses, with uncertain funding availability[163]. - The existing equity purchase facility may lead to substantial dilution for stockholders and downward pressure on the stock price[165]. - Future financing may not be available on acceptable terms, potentially leading to operational limitations and adverse effects on financial condition[173]. - The divestiture of the Elevai Skincare business includes potential earn-out payments contingent on revenue milestones, with no assurance of achievement[174]. - The company operates as a diversified holding company, increasing complexity in management and financial reporting across multiple industries[178]. - Acquisitions are a core growth strategy, but they involve significant risks, including integration challenges and potential underperformance of acquired businesses[184]. - Goodwill recorded on the consolidated balance sheet may be subject to impairment, which could adversely affect financial results[189]. Market and Competitive Landscape - The global biotechnology market was valued at approximately $1.37 trillion in 2022, with a projected CAGR of 12.8% from 2023 to 2030, driven by advancements in gene therapies and biologics[77]. - The precision machining market is expected to grow at a CAGR of approximately 8.1% from 2026 to 2033, with a valuation of approximately $123 billion in 2025[80]. - The global aerospace parts manufacturing market was valued at approximately $913 billion in 2023, with a projected CAGR of 4.2% from 2024 to 2030[80]. - The obesity and muscle preservation therapeutic market is highly competitive, with key players including Novo Nordisk, Eli Lilly, Pfizer, and Biohaven, all of which have greater financial and technical resources[93][94]. - Pacific Sun Packaging operates in a highly competitive industry, facing pricing pressure from larger competitors, which could adversely affect revenue and margins[210]. - The precision machining and specialty metals CNC market is competitive, with AGA Precision Systems differentiating itself through specialized machining capabilities and established customer relationships[96]. Regulatory and Compliance Issues - The company is subject to extensive government regulations regarding the research, development, and approval of its biologic drug candidates, which may change over time[125]. - The FDA has a goal date of ten months from the date of filing to review and act on a Biologics License Application (BLA) submission[135]. - A Complete Response Letter (CRL) indicates that the BLA cannot be approved in its present form, detailing specific deficiencies identified by the FDA[137]. - Post-marketing requirements (PMRs) may include Phase 4 studies to gain additional experience from the treatment of patients after initial marketing approval[138]. - Compliance with the International Traffic in Arms Regulations (ITAR) is mandatory for precision manufacturing operations, with annual registration renewal required[142]. - The company’s precision manufacturing operations are subject to federal and state occupational safety and health laws, with potential fines and citations for non-compliance[145]. - The company must comply with environmental regulations, including the Clean Air Act and Clean Water Act, to avoid fines and operational restrictions[146]. - The company’s specialty packaging operations must adhere to electrostatic discharge protection standards, which are often required by customers in the semiconductor industry[150]. - The company may face significant regulatory burdens if deemed an "investment company" under the Investment Company Act of 1940[224]. Operational Risks and Challenges - The company relies on a limited number of suppliers for raw materials, and disruptions could adversely affect the ability to fulfill customer orders[212]. - Disruptions in supply chains could increase costs and impair the ability to fulfill customer orders, adversely affecting revenue and margins[221]. - The company may face disputes or financial obligations related to earn-out and contingent consideration arrangements from acquisitions, impacting overall costs[190]. - The development of therapeutic product candidates could expose the company to significant legal and regulatory risks, affecting timelines and costs[197]. - AGA Precision Systems incurred significant repair and maintenance costs following acquisitions, which may require ongoing capital investment[215]. - The company has historically operated without a formal sales and marketing function, potentially limiting growth opportunities[216]. - Operations across multiple industries expose the company to diverse market risks, which may not mitigate overall risk as expected[217]. - A portion of revenue may depend on a limited number of key customers, risking significant adverse effects on revenue if relationships are not maintained[220]. - Non-compliance with anti-corruption and anti-bribery laws could expose the company to significant penalties and reputational harm[227]. Employee and Management Structure - The company has 32 full-time and 2 part-time employees, focusing on competitive compensation and a positive work environment to attract and retain talent[123]. - The principal executive office is located in Newport Beach, CA, with a monthly rent of $9,273.50 for a 1,650 square feet space[121]. - The company engages with institutional investors and industry participants to enhance awareness of its diversified business model and growth strategy[116]. - The company emphasizes flexible M&A and licensing models to create value for shareholders, allowing for strategic acquisitions and potential spin-offs[115].

Financial Performance - The company's revenue for 2025 decreased by 21.8% year-over-year to $29.7 million, primarily due to a 30.8% decline in hashprice from $54.45 to $37.68[16] - Gross profit for 2025 was $6.5 million, with a gross margin decline from 25% in 2024 to 22% in 2025, attributed to weaker hashprice[16] - The net loss for 2025 was $57.0 million, slightly improved from a net loss of $58.3 million in 2024[21] - Adjusted EBITDA for 2025 decreased to -$13.2 million, down from a positive $942k in 2024, due to revenue declines and increased expenses[21] - Total revenue for Soluna Holdings in 2025 was $29.717 million, a decrease of 21.8% from $38.021 million in 2024[29] - Cryptocurrency mining revenue decreased to $11.406 million in 2025, down 32.9% from $17.027 million in 2024[29] - Data hosting revenue also declined to $16.998 million, a decrease of 10.0% from $18.838 million in 2024[29] - The operating loss for 2025 was $33.681 million, an improvement from a loss of $47.523 million in 2024[29] - Net loss attributable to Soluna Holdings was $53.411 million in 2025, compared to a net loss of $63.334 million in 2024[29] - Basic and diluted loss per share improved to $2.38 in 2025 from $14.94 in 2024[29] - For the year ended December 31, 2025, the net loss before taxes was $(59,307) million, slightly improved from $(60,787) million in 2024[36] - Adjusted EBITDA for the year ended December 31, 2025, was $(13,229) million, compared to $942 million in 2024, indicating a significant decline in operational performance[39] Cash and Liquidity - Soluna's total cash position increased by 750% to $88.8 million, with approximately $142 million raised in capital during 2025[5] - The company entered 2026 with a current ratio of 1.9x, indicating a strong liquidity position to support future growth initiatives[8] - Cash and cash equivalents rose significantly to $76.423 million in 2025 from $7.843 million in 2024[26] - The company ended the period with cash and restricted cash totaling $88,843 thousand, a significant increase from $10,453 thousand at the beginning of the period[31] - Net cash used in operating activities was $9,149 thousand for 2025, an increase from $5,069 thousand in 2024, reflecting higher operational expenditures[31] - Net cash provided by financing activities reached $119,392 thousand in 2025, a substantial increase from $18,318 thousand in 2024, driven by various stock issuances[31] Operational Capacity and Projects - The operational capacity doubled in 2025, with the power pipeline expanding to over 4.3 GW, driven by new project developments[2] - Project Dorothy 2, with a capacity of 48 MW, was completed and fully operational in November 2025, enhancing profitability and customer satisfaction[6] - The construction of Project Kati 1 (83 MW) commenced in Q3 2025, with revenue generation expected in the first half of 2026[6] Expenses and Costs - SG&A expenses increased by $11.9 million year-over-year, driven by strategic investments in growth initiatives[16] - The company incurred total segment costs of revenue amounting to $24,255 thousand, with utility costs contributing $8,910 thousand and wages, benefits, and employee-related costs at $3,733 thousand[33] - The total segment cost of revenue for the year ended December 31, 2025, was $23,259 million, reflecting increased operational costs[37] - The company recognized stock-based compensation expenses of $10,566 thousand in 2025, up from $5,311 thousand in 2024, indicating increased employee incentives[31] Assets and Liabilities - Total assets increased to $187.944 million as of December 31, 2025, compared to $88.040 million in 2024[26] - Total liabilities increased to $75.698 million in 2025, up from $60.678 million in 2024[26] Fair Value Adjustments - The company reported a fair value adjustment of $23,680 thousand, which contributed positively to the cash flow from operating activities[31] - The company experienced a fair value adjustment loss of $23,681 million in 2025, significantly impacting the financial results[39] - The company reported a fair value adjustment loss of $118,000 in Q3 2025, compared to a significant loss of $22,047,000 in Q2 2025, suggesting improved asset valuation management[41]

Financial Performance - Revenue for 2025 decreased by 21.8% year-over-year to $29.7 million, primarily due to a 30.8% decline in hashprice[16][21] - Gross profit for 2025 was $6.5 million, with a gross margin drop from 25% in 2024 to 22% in 2025[16][21] - Adjusted EBITDA for 2025 declined to -$13.2 million, a decrease of $14.2 million from the previous year[21] - Total revenue for Soluna Holdings in 2025 was $29.717 million, a decrease of 21.8% from $38.021 million in 2024[29] - Cryptocurrency mining revenue decreased to $11.406 million in 2025, down 32.9% from $17.027 million in 2024[29] - Data hosting revenue also declined to $16.998 million, a decrease of 10.0% from $18.838 million in 2024[29] - Operating loss for 2025 was $33.681 million, an improvement from a loss of $47.523 million in 2024[29] - Net loss attributable to Soluna Holdings in 2025 was $53.411 million, compared to a net loss of $63.334 million in 2024[29] - Basic and diluted loss per share improved to $2.38 in 2025 from $14.94 in 2024[29] - Net loss for the year ended December 31, 2025, was $56,991, compared to a loss of $58,300 in 2024, representing a decrease of 2.2%[31] Cash and Liquidity - Soluna's total cash position increased by 750% to $88.8 million, with approximately $142 million raised in capital during 2025[5][16] - The current ratio improved to 1.9x, indicating a stronger liquidity position heading into 2026[8] - Cash and cash equivalents rose significantly to $76.423 million in 2025, compared to $7.843 million in 2024[26] - Cash and restricted cash at the end of the period rose to $88,843 from $10,453 at the beginning of the period, reflecting a significant increase[31] - Net cash used in operating activities increased to $9,149 in 2025 from $5,069 in 2024, indicating a higher cash outflow[31] Assets and Liabilities - Total assets increased to $187.944 million as of December 31, 2025, up from $88.040 million in 2024[26] - Total liabilities increased to $75.698 million in 2025, compared to $60.678 million in 2024[26] Project Developments - The power pipeline expanded to over 4.3 GW, driven by new project developments and partnerships[2][6] - The completion of Project Dorothy 2 (48 MW) in November 2025 enhanced operational efficiency and customer satisfaction[6][21] - Construction of Project Kati 1 (83 MW) commenced in Q3 2025, with revenue generation expected in the first half of 2026[6][21] - Soluna signed an MOU with Metrobloks for Project Kati 2, planning to develop over 300 MW of AI and HPC data center capacity[6] Operating Expenses - SG&A expenses increased by $11.9 million year-over-year, reflecting strategic investments in growth initiatives[16] - The company incurred depreciation expenses of $6,852, up from $6,152 in 2024, indicating increased asset utilization[31] - The company made significant investments in property, plant, and equipment totaling $28,065, compared to $8,853 in 2024, reflecting a focus on expansion[31] Segment Performance - Total segment cost of revenue was $24,255, with the highest costs attributed to utility expenses at $8,910 and wages at $3,733[33] - The company reported a segment operating income of $1,798, with a loss in Cryptocurrency Mining of $630 and a profit in Data Center Hosting Services of $2,677[33] - For the year ended December 31, 2025, the projected segment operating income is $1,798 million, indicating a potential recovery from the previous year's losses[36] Interest and Fair Value Adjustments - Interest expense, net for Q3 2025 was $838,000, compared to $1,196,000 in Q2 2025, with a total of $4,835,000 for the year ended December 31, 2025[41] - Fair value adjustment loss for Q3 2025 was $118,000, while the total for the year ended December 31, 2025 was $23,681,000[41] Non-controlling Interests - Contributions from non-controlling interest increased to $29,559 from $14,735, indicating stronger financial backing from minority stakeholders[31]

Financial Position - Neumora reported a cash position of $182.5 million as of December 31, 2025, expected to support operations into Q3 2027[15]. - Neumora's total assets decreased to $191.0 million as of December 31, 2025, down from $317.0 million in 2024[20]. Research and Development - Research and development expenses for Q4 2025 were $44.7 million, a decrease from $45.9 million in Q4 2024; full-year R&D expenses were $176.1 million, down from $200.9 million in 2024[15]. - NMRA-511 demonstrated a Cohen's d effect size of 0.34 on the CMAI total score and 0.51 on the CMAI aggression sub-factor score at Week 8 in a pre-specified analysis of 53 patients[6]. - NMRA-898 has shown an approximately 80-100-hour half-life in humans, supporting potential once-daily dosing[13]. - Neumora plans to initiate a Phase 2 study with NMRA-511 in Alzheimer's disease agitation in Q1 2027[5]. - NMRA-215's 12-week diet-induced obesity study supports its potential use in switch and maintenance settings, with clinical studies expected to start in Q1 2027[9]. Expenses - General and administrative expenses for Q4 2025 were $13.8 million, compared to $17.0 million in Q4 2024; full-year G&A expenses were $60.1 million, down from $62.5 million in 2024[15]. - The net loss for Q4 2025 was $59.4 million, slightly higher than the $58.8 million loss in Q4 2024; the full-year net loss was $236.9 million, compared to $243.8 million in 2024[15]. Clinical Trials - The KOASTAL-2 and -3 studies were fully enrolled in Q1 2026, with over 400 patients in each study, and a joint topline data readout is expected in Q2 2026[7].